BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. BioCryst Pharmaceuticals, Inc. stands third among them.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a biotechnology company specializing in rare disease therapeutics, reported strong operational and financial momentum in 2025, driven primarily by its flagship product, ORLADEYO, an oral therapy for hereditary angioedema (HAE). The company also markets intravenous peramivir for influenza and is advancing pipeline candidates such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema.

In Q2 2025, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) achieved record revenue of $163.4 million, a 49.4% year-over-year increase, fueled by record new patient prescriptions for ORLADEYO. This growth contributed to a net income of $5.1 million, a notable turnaround from a loss in the prior year. The company also strengthened its balance sheet, reducing debt by $50 million following the sale of its European ORLADEYO business, enhancing financial flexibility for future expansion.

Looking forward, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) maintains global ORLADEYO revenue guidance of $580–600 million for 2025, despite the European divestiture. The company is also exploring strategic acquisitions of late-stage or commercial rare disease assets to expand its portfolio. Its pipeline continues to progress, including an ongoing Phase 1 trial of BCX17725 and other preclinical programs, underscoring its commitment to innovation in rare disease therapies.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.